DOCSLIB.ORG

Recommended Methods for the Identification and Analysis of Piperazines in Seized Materials

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recommended Methods for the Identification and Analysis of Piperazines in Seized Materials Recommended methods for the Identification and Analysis of Piperazines in Seized Materials MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits: UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Piperazines in Seized Materials MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS New York, 2013 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases, but any modification has to be validated before it is integrated into laboratory routines. ST/NAR/47 Original language: English © United Nations, January 2013. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements UNODC’s Laboratory and Scientific Section (LSS), headed by Dr. Justice Tettey, wishes to express its appreciation and thanks to Ms. Pamela Smith for the prepara- tion of the first draft of this manual. LSS would also like to thank Mr. Jeffery Comparin of the United States Drug Enforcement Administration, Mr. Paul Loo, Mr. Chad Mehaux and Ms. Valérie Bélisle of the Canadian Border Services Agency and Dr. Mark Baron of the University of Lincoln, United Kingdom for their expert reviews and valuable contribution. The preparation of this manual was coordinated by Dr. Conor Crean and the con- tributions of UNODC staff and interns, Ms. Bridgette Webb and Mr. Diego Pazos are gratefully acknowledged. iii Contents Page 1. Introduction ..................................................... 1 1.1 Background .................................................. 1 1.2 Purpose and use of the Manual ................................ 2 2. General aspects ..................................................... 5 2.1 Description of the pure compounds. ............................ 5 2.2 Licit uses ..................................................... 8 2.3 Control status ................................................ 8 2.4 Illicit products/use ............................................ 8 2.5 Pharmacology ............................................ 9 3. Illicit manufacture of piperazines ..................................... 10 3.1 Illicit manufacture ......................................... 10 4. Qualitative and quantitative analysis of materials containing piperazines .. 12 4.1 Sampling .................................................... 12 4.2 Solubility ..................................................... 12 4.3 Screening tests ............................................... 13 4.4 Microcrystalline tests .......................................... 17 4.5 Thin-layer chromatography (TLC) .............................. 19 4.6 Gas chromatography (GC) with flame ionization detection (GC-FID) 23 4.7 Gas chromatography-mass spectrometry (GC-MS) ................ 25 4.8 Gas chromatography-infrared detection (GC-IRD) ................ 28 4.9 High pressure liquid chromatography (HPLC) .................... 29 4.10 Capillary electrophoresis (CE) .................................. 32 4.11 Fourier transform infrared (FTIR) spectroscopy .................. 33 5. Library information ................................................. 35 5.1 Ultraviolet (UV) spectrophotometry ............................. 35 5.2 GC-MS data for selected piperazines ............................ 35 Additional reading ..................................................... 37 References ............................................................ 43 v 1. Introduction 1.1 Background Piperazine, a heterocyclic six-membered ring compound which contains two nitro- gens in the 1 and 4 positions, is a cyclic member of the ethylenediamine group of molecules [1, 2]. The abuse of substituted derivatives of piperazine was first reported in the United States in 1996 and has, since then, spread to a number of countries worldwide [3]. The large scale use of synthetic derivatives of piperazine as substi- tutes or mimics of “ecstasy” started in New Zealand in the early 2000s and became common in Europe after 2004 [4]. The first piperazine derivative encountered was 1-benzylpiperazine (BZP), one of a group of phenyl and benzyl substituted piperazines that have become prevalent worldwide, especially in traditional 3,4-methylenedioxymethamphetamine (MDMA) markets. Other widely used piperazines include 1-(3-chlorophenyl)piperazine, (mCPP) and 1-(3-trifluoromethylphenyl)piperazine (TFMPP), the latter of which is commonly found in combination with BZP. BZP itself is a central nervous system stimulant with a potency of 10% that of d-amfetamine [4]. It has been reported to stimulate the release of dopamine, noradrenaline, and serotonin, and also inhibit their reuptake. The substances are thus amfetamine mimics and predominantly found in tablet form either alone, in com- bination with other piperazines or with amfetamine, cocaine, ketamine or MDMA. Neither BZP nor any other substituted piperazine are listed in the Schedules of the United Nations 1971 Convention on Psychotropic Substances. However, in 2007, the International Narcotics Control Board (INCB) requested the World Health Organization (WHO) to consider reviewing piperazine derived compounds for pos- sible scheduling under the 1971 Convention. Independently, many countries have introduced legislation controlling the use of BZP. This includes the United States and the countries of the European Union (EU), which submitted BZP for EU control in 2008 following a risk assessment using the early warning system of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) [5]. 1 2 Recommended methods for the identification and analysis of piperazines in seized materials 1.2 Purpose and use of the Manual The present Manual is one in a series of similar publications dealing with the iden- tification and analysis of various classes of drugs under international control. These manuals are the outcome of a programme pursued by UNODC since the early 1980s, aimed at the harmonization and establishment of recommended methods of analysis for national drug analysis laboratories. This Manual was prepared taking into account the Commission on Narcotic Drugs 2012 resolution: 55/1 “Promoting international cooperation in responding to the challenges posed by new psychoactive substances”, which encourages the United Nations Office on Drugs and Crime and other relevant international organizations, upon request, to provide Member States with technical assistance, including by supporting forensic and toxicological capability, to respond to the challenges posed by new psychoactive substances. In accordance with the overall objective of the series, the present manual suggests approaches that may assist drug analysts in the selection of methods appropriate for the sample under examination and provide data suitable for the purpose at hand, leaving room also for adaptation to the level of sophistication of different laboratories and various legal requirements. The majority of methods included in this manual are validated, methods which have been used for a number of years in reputable laboratories and as part of inter-laboratory studies, collaborative exercises and pro- ficiency tests. The reader should be aware, however, that there are a number of other methods, including those published in the forensic science literature, which may also produce acceptable results. Any new method that is to be used in the reader’s laboratory must be validated and/or verified prior to routine use. In addition, there are a number of more sophisticated approaches, but they may not be necessary for routine operational applications. Therefore, the methods described here should be understood as guidance, that is, minor modifications to suit local circumstances should not affect the validity of the results. The choice of the meth- odology and approach to analysis, as well as the decision whether or not additional methods are required, remain with the analyst and may also be dependent on the availability of appropriate instrumentation and the level of legally acceptable proof in the jurisdiction within which the analyst works. Attention is also drawn to the vital importance of the availability to drug analysts of reference materials and books on drugs of abuse and the analytical techniques used for their identification. Moreover, the analyst must of necessity keep abreast of current trends in drug analysis, consistently following current analytical and foren- sic science literature. UNODC’s Laboratory and Scientific Section would welcome observations on the contents and usefulness of the present Manual. Comments and suggestions may be addressed to: Recommended methods for the identification and analysis
Load more

Recommended publications
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • United States Patent Office
    Patented Feb. 11, 1947 2,415,786 UNITED STATES PATENT OFFICE UNSYMMETRICALLY SUBSTITUTED PPERAZINES Johannes S. Buck, East Greenbush, and Richard Baltzly, New York, N. Y., assignors to Bur roughs Welcome & Co. (U. S. A.) Inc., New York, N.Y., a corporation of New York No Drawing. Application January 6, 1944, serial No. 517,224 9 Claims. (C. 260-268) 2 This invention relates to N-monosubstituted According to the present invention, these diffi and N-N'-unsymmetrically disubstituted piper culties are overcome by treating piperazine with azines and has for an object to provide new com a halide of benzyl or of a substituted benzyl to positions of the above type and a novel and im form a reaction mixture containing, in addition proved method of making the same. to unreacted piperazine and di-N-N'- Substituted Another object is to provide a method of mak piperazine, a substantial amount of N-mono sub ing and isolating the above substances which is stituted piperazine separating the mono-N-sub Suitable for commercial Operation. stituted piperazine from the unreacted piperazine In our copending application Serial No. 476,914, and the disubstituted piperazine, introducing the filed February 24, 1943, of which the present ap O desired substituent on to the second N' nitrogen plication is a continuation in part and in our atom of the mono-N-substituted piperazine, then Copending application Serial No. 517,225, filed removing the benzyl or substituted benzyl group January 6, 1944, which is also a continuation in by catalytic hydrogenation. part, We have described certain methods for mak As catalysts for this hydrogenation, platinum, ing and isolating substituted piperazines of the palladium and nickel are all suitable, but We pre type fer in general to use palladium since, while CEI-CI equally or perhaps more effective in removing a benzyl group, it is practically devoid of any N /N-R tendency to reduce aromatic rings.
    [Show full text]
  • Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; a Web-Based Approach
    ORIGINAL RESEARCH published: 09 February 2021 doi: 10.3389/fpsyt.2020.632405 Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach Valeria Catalani 1*, Davide Arillotta 1, John Martin Corkery 1, Amira Guirguis 1,2, Alessandro Vento 3,4,5 and Fabrizio Schifano 1 1 Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 2 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 3 Department of Mental Health, ASL Roma 2, Rome, Italy, 4 Addictions’ Observatory (ODDPSS), Rome, Italy, 5 Department of Psychology, Guglielmo Marconi University, Rome, Italy COVID-19-related disruptions of people and goods’ circulation can affect drug markets, especially for new psychoactive substances (NPSs). Drug shortages could cause a change in available NPS, with the introduction of new, unknown, substances. The aims of the current research were to use a web crawler, NPSfinder®, to identify and categorize emerging NPS discussed on a range of drug enthusiasts/psychonauts’ websites/fora at the time of the pandemic; social media for these identified NPS were screened as Edited by: well. The NPSfinder® was used here to automatically scan 24/7 a list of psychonaut Ornella Corazza, University of Hertfordshire, websites and NPS online resources. The NPSs identified in the time frame between United Kingdom January and August 2020 were searched in both the European Monitoring Center Reviewed by: for Drugs and Drug Addictions (EMCDDA)/United Nations Office on Drugs and Crime Simona Zaami, Sapienza University of Rome, Italy (UNODC) databases and on social media (Facebook, Twitter, Instagram, Pinterest, Laura Hondebrink, and YouTube) as well, with a content qualitative analysis having been carried out on University Medical Center reddit.com.
    [Show full text]
  • Recent Progress Toward the Asymmetric Synthesis of Carbon-Substituted Piperazine Pharmacophores and Oxidative Related Heterocycles RSC Medicinal Chemistry
    Volume 11 Number 7 July 2020 RSC Pages 735–850 Medicinal Chemistry rsc.li/medchem ISSN 2632-8682 REVIEW ARTICLE Plato A. Magriotis Recent progress toward the asymmetric synthesis of carbon-substituted piperazine pharmacophores and oxidative related heterocycles RSC Medicinal Chemistry View Article Online REVIEW View Journal | View Issue Recent progress toward the asymmetric synthesis Cite this: RSC Med. Chem.,2020,11, of carbon-substituted piperazine pharmacophores 745 and oxidative related heterocycles Plato A. Magriotis † The important requirement for approval of a new drug, in case it happens to be chiral, is that both enantiomers of the drug should be studied in detail, which has led synthetic organic and medicinal chemists to focus their attention on the development of new methods for asymmetric synthesis especially of relevant saturated N-heterocycles. On the other hand, the piperazine ring, besides defining a major class of saturated N-heterocycles, has been classified as a privileged structure in medicinal chemistry, since it is more than frequently found in biologically active compounds including several marketed blockbuster drugs such as Glivec (imatinib) and Viagra (sildenafil). Indeed, 13 of the 200 best-selling small molecule drugs in 2012 contained a piperazine ring. Nevertheless, analysis of the piperazine substitution pattern reveals a lack Creative Commons Attribution 3.0 Unported Licence. of structural diversity, with almost every single drug in this category (83%) containing a substituent at both Received 16th February 2020, the N1- and N4-positions compared to a few drugs having a substituent at any other position (C2, C3, C5, Accepted 27th April 2020 and C6). Significant chemical space that is closely related to that known to be biologically relevant, therefore, remains unexplored.
    [Show full text]
  • “Ecstasy” Tablets
    Department of Alcohol & OSAM-O-GRAM Drug Addiction Services Wright State University Dateline: Ohio June 2008-January 2009 Statewide reports of piperazines in adulterated “Ecstasy” tablets Increases in Piperazine Availability surfaced in northeast Ohio, “We did just see one with mCPP, but In January 2008, the OSAM Network received initial reports that’s not as popular as BZP. The informant who brought it was told it was from crime lab professionals of piperazine-containing pressed ‘Triple E’ or ‘Super Ecstasy’ by the dealer. Most of the tablets don’t look tablets that appeared to be sold as Ecstasy. One year later, any different than Ecstasy but we did find one micro tablet, which was half availability of pressed tablets containing piperazines has the size of a normal Ecstasy tablet and it ended up being mCPP.” A lab drastically increased throughout the state (Table below). in the central Ohio area reported most of the pressed tablets Piperazine cases now outnumber the cases of MDMA- analyzed there contain polydrug combinations, “The most common containing Ecstasy tablets analyzed by crime labs across Ohio. combination in our lab is BZP/TFMPP/MDMA/Methamphetamine. A crime lab professional from the central Ohio area said, “We In the last year, only seven cases have been BZP alone.” analyzed our first benzylpiperazine cases in January 2008, and it’s been fairly steady since that time.” Piperazines vs. Ecstasy(MDMA) Crime lab professionals reported piperazines are indistinguishable Table 1: Availability of piperazine tablets according to crime from traditional Ecstasy tablets. A crime lab professional from lab professionals the northwest Ohio area noted, “Most lab chemists would tell you just Jan.
    [Show full text]
  • Legal Party Pills and Their Use by Young People in New Zealand: a Qualitative Study
    LEGAL PARTY PILLS AND THEIR USE BY YOUNG PEOPLE IN NEW ZEALAND: A QUALITATIVE STUDY FINAL REPORT OF FINDINGS First submitted December 2006 Revised June 2007 Janie Sheridan, PhD MRPharmS, MPS(NZ), BPharm(Hons), BA(Hons) Rachael Butler, BA The School of Pharmacy The University of Auckland New Zealand i Suggested citation: Sheridan, J. & Butler, R. (2007) Legal party pills and their use by young people in New Zealand: a qualitative study. Final report of findings (revised June 2007). University of Auckland: Auckland ii TABLE OF CONTENTS Acknowledgements.................................................................................................................. v Glossary................................................................................................................................... vi Executive Summary of Results............................................................................................. vii 1.0 Introduction ....................................................................................................................... 1 1.1 Structure of this report .........................................................................................1 1.2 Background literature...........................................................................................1 1.3 Rationale for researching young people’s use of party pills................................4 2.0 Study Aims ......................................................................................................................... 6 3.0 Methods
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Pharmacologyonline 2: 252-260 (2006) Colovic Et Al
    Pharmacologyonline 2: 252-260 (2006) Colovic et al. THE 1-(2,3-DICHLOROPHENYL)-PIPERAZINE-TO-ARIPIPRAZOLE RATIO AT STEADY STATE IN RATS AND SCHIZOPHRENIC PATIENTS Milena Colovica, Giuseppe Campianib, Stefania Butinib, Alberto Parabiaghia and Silvio Cacciaa aIstituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy bDipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Universita` di Siena, Siena, Italy Summary Aripiprazole metabolism includes N-dealkylation to 1-(2,3-dichlorophenyl)-piperazine which was present as a minor metabolite in serum of eight schizophrenic outpatients taking 5-15 mg/day. As phenylpiperazines concentrate in the brain, causing serotonin receptor-related effects, the authors examined the compounds’ concentrations in brain of rats given 10 mg/kg aripiprazole dihydrochloride orally, approximately every half-life for five half-lives, and evaluated the metabolite-to-parent drug ratio at steady state. The metabolite had higher brain uptake (about 26) than aripiprazole (about 5) and therefore the metabolite-to-parent drug ratio was higher in brain (0.43 ± 0.07, on molar basis) than in blood (0.08 ± 0.01). However, assuming that the compounds concentrate in human brain to the same extent as in the rat, one can conclude that at the site of action the metabolite represents only about 6% of aripiprazole. It is therefore conceivable that the metabolite contributes to the central effects of aripiprazole for rats, but this is unlikely for patients taking therapeutic doses. Key Words: Aripiprazole; 1-(2,3-dichlorophenyl)-piperazine; brain-to-blood distribution; metabolite-to-parent drug ratio With a pharmacological profile that differs from currently marketed antipsychotics for the treatment of schizophrenia and schizoaffective disorders, aripiprazole is a first-in-class drug.
    [Show full text]
  • Piperazine (Street Names: “TFMPP” Or “Molly”. Often Found in Combination with BZP: “A2”, “Legal E” Or “Legal X”)
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 1-[3-(Trifluoro-methyl)-phenyl]piperazine (Street Names: “TFMPP” or “Molly”. Often found in combination with BZP: “A2”, “Legal E” or “Legal X”) October 2019 Introduction: Illicit Uses: 1-[3-(Trifluoro-methyl)-phenyl]piperazine (TFMPP) is TFMPP is being promoted as a legal alternative to an industrial chemical. It is often abused in combination MDMA at raves (all-night dance parties) as TFMPP or with benzylpiperazine (BZP), a schedule I controlled “Molly” and is often sold in combination with BZP as substance. The Drug Enforcement Administration (DEA) “ecstasy”, or “A2", “legal E” or “legal X” in order to enhance temporarily controlled TFMPP in 2002 as a schedule I its spectrum of effects. TFMPP may be abused alone for hallucinogen under the Controlled Substances Act (CSA) its hallucinogenic effects. TFMPP is generally administered because of its abuse potential and lack of accepted orally as either powder, tablets or capsules. Other routes medical use or safety. However, based on the scientific of administration include smoking and snorting. and medical evaluation conducted by the Food and Drug Administration (FDA) and the National Institute on Drug User Population: Abuse (NIDA), the Department of Health and Human Youth and young adults are the main abusers of Services (DHHS) did not recommend control of TFMPP. TFMPP. Accordingly, TFMPP was no longer controlled under the CSA after March 18, 2004. Recently, there has been an Illicit Distribution: escalation in the abuse of TFMPP in the United States as The National Forensic Laboratory Information System evidenced by the increasing encounters of this substance (NFLIS) is a DEA database that collects scientifically by law enforcement officials in various states and the verified data on drug items and cases submitted to and District of Columbia.
    [Show full text]
  • Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com
    Hallucinogens And Dissociative Drug Use And Addiction Introduction Hallucinogens are a diverse group of drugs that cause alterations in perception, thought, or mood. This heterogeneous group has compounds with different chemical structures, different mechanisms of action, and different adverse effects. Despite their description, most hallucinogens do not consistently cause hallucinations. The drugs are more likely to cause changes in mood or in thought than actual hallucinations. Hallucinogenic substances that form naturally have been used worldwide for millennia to induce altered states for religious or spiritual purposes. While these practices still exist, the more common use of hallucinogens today involves the recreational use of synthetic hallucinogens. Hallucinogen And Dissociative Drug Toxicity Hallucinogens comprise a collection of compounds that are used to induce hallucinations or alterations of consciousness. Hallucinogens are drugs that cause alteration of visual, auditory, or tactile perceptions; they are also referred to as a class of drugs that cause alteration of thought and emotion. Hallucinogens disrupt a person’s ability to think and communicate effectively. Hallucinations are defined as false sensations that have no basis in reality: The sensory experience is not actually there. The term “hallucinogen” is slightly misleading because hallucinogens do not consistently cause hallucinations. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com How hallucinogens cause alterations in a person’s sensory experience is not entirely understood. Hallucinogens work, at least in part, by disrupting communication between neurotransmitter systems throughout the body including those that regulate sleep, hunger, sexual behavior and muscle control. Patients under the influence of hallucinogens may show a wide range of unusual and often sudden, volatile behaviors with the potential to rapidly fluctuate from a relaxed, euphoric state to one of extreme agitation and aggression.
    [Show full text]
  • A Straightforward Route to Enantiopure Pyrrolizidines And
    Molecules 2001, 6, 784-795 molecules ISSN 1420-3049 http://www.mdpi.org Biologically Active 1-Arylpiperazines. Synthesis of New N-(4- Aryl-1-piperazinyl)alkyl Derivatives of Quinazolidin-4(3H)-one, 2,3-Dihydrophthalazine-1,4-dione and 1,2-Dihydropyridazine- 3,6-dione as Potential Serotonin Receptor Ligands Piotr Kowalski1,*, Teresa Kowalska1, Maria J. Mokrosz2, Andrzej J. Bojarski2 and Sijka Charakchieva-Minol2 1 Institute of Organic Chemistry and Technology, Cracow University of Technology, 24 Warszawska str., 31-155 Cracow, Poland; 2 Department of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna str., 31-343 Cracow, Poland * Author to whom correspondence should be addressed; e-mail: [email protected] Received: 26 February 2001; in revised form: 28 August 2001 / Accepted: 28 August 2001 / Published: 31 August 2001 Abstract: The synthesis of a series of new n-propyl and n-butyl chain containing 1-aryl- piperazine derivatives of quinazolidin-4(3H)-one (7) 2-phenyl-2,3-dihydrophthalazine-1,4- dione (8) and 1-phenyl-1,2-dihydropyridazine-3,6-dione (9) as potential serotonin receptor ligands is described. Keywords: Arylpiperazines, lactams, serotonin receptor ligands. Introduction Early studies by Hibert et al. have shown that there are two basic pharmacophore groups common to all five classes of 5-HT1A receptor ligands: a basic nitrogen atom and an aromatic ring with its centre positioned at a distance of 5.2-5.7 Å [1]. Since then several attempts have been made to extend that model, but the large diversity of ligand structures made definition of general interaction modes Molecules 2001, 6 785 impossible.
    [Show full text]